Msi High News Today

Dr Kim offers key perspective for MSI-high patients based on data presented at ASCO 2024.

The European Commission has granted marketing authorization to dostarlimab paired with carboplatin and paclitaxel in adults with dMMR/MSI-H primary advanced or recurrent endometrial cancer who are eligible to receive systemic treatment.

A urologic oncology fellow provides a comprehensive overview of systemic therapy options for patients with prostate cancer.

Dr Marshall describes the impacts of microsatellite stability and instability on metastatic colorectal cancer.

Experts on advanced ovarian cancer give detailed insights on the role of biomarker testing and identify important biomarkers.

Key opinion leaders in differentiated thyroid cancer take a moment to define radioiodine refractory disease and consider its implications in establishing a treatment pathway.

In his closing thoughts, Dr Marshall shares final takeaways from the 2023 ASCO GI Cancers Symposium.

Opening their discussion on colorectal cancer, expert panelists consider its growing prevalence and highlight key molecular subtypes.